Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

Series B

Skylo escapes stealth with $116m
SoftBank has led a $103m series B round for the IoT network and hub developer, a spinout of Stanford, that made up one of two rounds it has raised.
HepaRegenix heaps on $12.2m
University Hospital Tübingen's liver disease treatment spinout HepaRegenix has raised $21.6m in all following a series B round that will fund trials of its first candidate.
Soft Robotics handles $23m series B
Harvard-founded industrial robot supplier Soft Robotics welcomed corporates Yamaha, Honeywell, Fanuc and Tekfen for its series B round.
TScan eases to $35m series B close
Subsidiaries of Astellas and Novartis co-led a series B round that took Harvard's cancer treatment developer's overall funding to $60m.
ReadCoor scores $27m
Pavilion Capital and Hansjörg Wyss featured in a series B round for Harvard-founded ReadCoor, whose existing shareholders also include Lilly Asia Ventures.
Deep Genomics dives for $40m
Deep Genomics will use the money to advance drug candidates created through its AI drug development model, based on research by Toronto faculty.
Soul Machines personifies $40m series B
University of Auckland Inventors Fund has contributed to a $40m series B round for AI-based avatar developer Soul Machines, with the investment led by Temasek.
Virtual Incision sews up $20m
The colectomy-focused robotic surgical device developer has now assembled $51.7m having spun out from University of Nebraska Medical Center in 2006.

Other News

Eyevensys eventuates $30m
Paris Descartes University's gene therapy developer has raised $42.1m altogether following a series B featuring existing investors including Inserm Transfert Initiative.
Trifo cleans up with $15m series B
Trifo, developer of a cleaning-based surveillance system, increased its total funding to $26m in a round that included Yidu Cloud.
MyGene clips $14m series B
Chinese Academy of Sciences-owned Cash Capital was among the investors in precision cancer screening business MyGene Diagnostics' second funding round.
Skyryse surprises the panel to win $13m
Already backed by Stanford University, autonomous helicopter technology business Skyryse has now obtained $38m altogether.
Cellestia observes $20.4m
EPFL's cancer drug developer Cellestia Biotech has extended its funding haul to $48.6m in a series B round that featured existing investor PPF Group.
ImCheck imports $53m in series B cash
Pfizer Ventures led the immuno-oncology drug developer's latest round, which was spun out of Institut Paoli-Calmettes with the help of Satt Sud-Est and Inserm Transfert.

Editor's Picks

Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Canvas paints $9m picture
Canvas Network, an online education platform developed by learning management software (LMS) provider Instructure which received $9.1m investment for the platform, has begun offering free and open online courses.
WRF finds its Resolve
In May 2010, Resolve raised $2m in the initial close of its A round before bringing in a corporate venturing unit later.
Imperial helps PsiOxus raise $34m
UK-listed investment fund Imperial Innovations joins GlaxoSmithKline's SR One, fund manager Invesco Perpetual and Lundbeckfond Ventures, backing the d cancer treatment company.
test reg